desogestrel
Trade name: Mercilon
Approved
Dec 10, 1992
Desogestrel is a progestin medication which is used in birth control pills. It is also used in the treatment of menopausal symptoms in women. The medication is available and used alone or in combination with an estrogen. It is taken by mouth. — Wikipedia
Clinical trial activity
99 trials · 82 clinical orgs · 21 marketing orgs
Earliest trial started Nov 1, 2001 (NCT00725413)
Timeline
1990s
- Dec 10, 1992
Earliest FDA Approval
- Dec 14, 1992
Johnson and Johnson — NDA Secondary Org
- Apr 22, 1998
Teva — NDA Secondary Org
- Aug 12, 1999
Duramed Research — Marketing Organization
2000s
- Dec 20, 2000
Aspen Pharmaceuticals — NDA Secondary Org
- Oct 3, 2001
Organon — Marketing Organization
- Oct 3, 2001
Organon — NDA Secondary Org
- Apr 5, 2002
Barr Laboratories — Marketing Organization
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
- Jul 29, 2005
Watson Pharmaceuticals — Marketing Organization
- Jan 24, 2006
Mayne Pharma — Marketing Organization
- Jul 17, 2006
Organon — First NDA Organization
- Jul 17, 2006
Organon — NDA Organization
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
2010s
- Feb 25, 2011
Endo Pharmaceuticals — Marketing Organization
- Feb 25, 2011
Apax Partners — Marketing Organization
- Apr 2, 2012
Glenmark Pharmaceuticals — Marketing Organization
- Mar 7, 2013
Lupin — Marketing Organization
- Jul 12, 2013
Novast Labs — Marketing Organization
- Aug 30, 2013
Mylan — Marketing Organization
- Apr 30, 2015
Vintage — Marketing Organization
- Aug 12, 2015
Exeltis — Marketing Organization
- Mar 22, 2017
Aurobindo Pharma — Marketing Organization
- Jun 5, 2017
Accord Research — Marketing Organization
- Jun 5, 2017
Naari Pte Ltd — Marketing Organization
- Dec 11, 2019
Amneal Pharmaceuticals — Marketing Organization
2020s
- Jan 13, 2021
Teva — Marketing Organization
- Dec 9, 2021
Dr. Reddy's Laboratories — Marketing Organization
Indications
Approved for
Studied for
- Abortion, Induced · Phase 4
- Acne Vulgaris · Phase 4
- Adolescent · Phase 4
- Anemia, Sickle Cell · Phase 4
- Biological Availability · Phase 1
- Chlamydia Infections · Phase 4
- Contraception · Phase 4
- Contraception, Postcoital · Phase 4
- Contraceptive Agents · Phase 4
- Contraceptives, Oral · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Dysmenorrhea · Phase 4
- Endometriosis · Phase 4
- Exercise · Phase 3
- Family Planning Services · Phase 3
- Fertilization in Vitro · Phase 4
- Growth and Development · Phase 4
- Healthy Volunteers · Phase 4
- Hemorrhage · Phase 4
- Hemostasis · Phase 2
- HIV · Phase 4
- HIV Infections · Phase 4
- Infertility · Phase 4
- Infertility, Female · Phase 3
- Lactation Disorders · Phase 4
- Leiomyoma · Phase 4
- Light · Phase 4
- Live Birth · Phase 4
- Medicine, Chinese Traditional · Phase 4
- Menstruation Disturbances · Phase 4
- Metrorrhagia · Phase 3
- Neisseriaceae Infections · Phase 4
- Opioid-Related Disorders · Phase 4
- Ovarian Diseases · Phase 2
- Ovarian Follicle · Phase 1
- Ovulation Induction · Phase 1/Phase 2
- Polycystic Ovary Syndrome · Phase 4
- Postpartum Period · Phase 4
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 4
- Premenstrual Syndrome · Phase 4
- Primary Ovarian Insufficiency · Phase 3
- Prostatic Neoplasms · Phase 2
- Sexual Behavior · Phase 4
- Sleep Apnea, Central · Phase 2/Phase 3
- Therapeutic Equivalency · Phase 1
- Thinness · Phase 4
- Vaginosis, Bacterial · Phase 4
Mechanism of action
- Progesterone receptorAGONIST
PGR agonist
Combination products
desogen
with ethinyl estradiol
Also known as bekyree, cyclessa, desogestrel; ethinyl, emoquette, enskyce, isibloom, kalliga, kariva, kimidess, mircette, nuvaring, ortho-cept, pimtrea, velivet, viorele, volnea
Approval history
- approvedDec 10, 1992
Chemistry & pharmacology
SMILES
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC- Mol. weight
- 324.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaDesogestrel ↗
- ChEMBLCHEMBL1533 ↗
- ChEMBLCHEMBL1531 ↗
- ChEMBLCHEMBL1697750 ↗
- NCATS81K9V7M3A3 ↗
- NCATS304GTH6RNH ↗
- WikipediaEthinylestradiol/etonogestrel ↗
Also known as
- 13-ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
- 13-ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
- 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
- 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)-
- 3-ketodesogestrel
- 3-ketodesogestrel
- 3-ketodesogestrel
- 3-keto-desogestrel
- 3-oxodesogestrel
- 3-oxodesogestrel
- 3-oxodesogestrel
- 3-oxodesogestrel
- 3-oxo desogestrel
- aizea
- cerazette
- cerazette
- cerazette
- cerazette
- cerelle
- combeq
- combiphasic ee-dsg contraceptive
- desogestrel
- desogestrel
- desogestrel
- desogestrel
- desogestrel
- desogestrel
- desogestrelum
- desogestrelum
- desomono
- ethinyl estradiol-desogestrel combination
- ethonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- etonogestrel
- étonogestrel
- étonogestrel
- etonogestrelum
- etonogestrelum
- etonorgestrel
- feanolla
- implanon
- implanon
- implanon
- implanon
- implanon
- mercilon
- mercilon
- nacrez
- nexplanon
- nexplanon
- nexplanon
- nexplanon
- nourypharma brand of 3-keto-desogestrel
- nuvaring
- nuvaring
- org 2969
- org 2969
- org 2969
- org 2969
- org 2969
- org 2969
- org-2969
- org-2969
- org-3236
- org-3236
- organon brand of 3-keto-desogestrel
- zelleta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07269327 | Phase 1 | Nov 24, 2025 | Merck KGaA |
| NCT06304220 | N/A | Jul 31, 2024 | NextFertility Valencia |
| NCT05730205 | Phase 4 | Jun 8, 2023 | University of Pennsylvania |
| NCT05002738 | Phase 4 | Sep 10, 2021 | University of Colorado, Denver |
| NCT04941833 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2021 | Rajavithi Hospital, Bangkok |
| NCT04728659 | Phase 4 | Oct 1, 2020 | Casa di Cura Privata del Policlinico SpA |
| NCT04422028 | Phase 1 | Jan 11, 2020 | Grunenthal, Laboratorios Andromaco |
| NCT03953716 | Phase 4 | Jun 22, 2019 | Chinese Academy of Medical Sciences |
| NCT03895099 | Phase 3 | Apr 30, 2019 | Centre Hospitalier Intercommunal Creteil, Merck |
| NCT03656289 | Phase 1 | Oct 1, 2018 | University of Colorado, Denver |
| NCT03282799 | Phase 2 | Sep 30, 2018 | Infectious Disease Institute, Kampala, Uganda, University of Nebraska, University of Pittsburgh |
| NCT03353857 | Phase 1 | Nov 29, 2017 | Bayer |
| NCT03197077 | Phase 3 | Jul 1, 2017 | Free University of Brussels, Merck |
| NCT02669238 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2017 | Centre Hospitalier Universitaire de la Réunion |
| NCT03120728 | Phase 4 | May 16, 2017 | University of Southern California |
| NCT02866643 | Phase 3 | Oct 1, 2016 | Stanford University |
| NCT05174195 | N/A | Aug 15, 2016 | University of Geneva |
| NCT02852265 | Phase 4 | Aug 1, 2016 | Merck, University of California, Davis |
| NCT02757287 | Phase 4 | May 1, 2016 | Universidad Autonoma de Barcelona, University Hospital Quirón Dexeus, Barcelona |
| NCT02445989 | Phase 4 | May 1, 2016 | National Institutes of Health (NIH), University of Washington |
Organizations
Research & Development (82)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 23 | 16 | 3 | 2001 |
| Bayer | For profit | 7 | 5 | 4 | 2003 |
| Teva | For profit | 4 | 4 | 3 | 2007 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 1 | 2 | 2003 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 2 | 2003 |
| Organon | For profit | 3 | 0 | 2 | 2005 |
| University of Pennsylvania | Academic/Hospital | 3 | 3 | 3 | 2011 |
| University of Pittsburgh | Academic/Hospital | 3 | 3 | 2 | 2005 |
| University of Sao Paulo | Academic/Hospital | 3 | 3 | 2 | 2007 |
| Cairo University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 2 | 0 | 1 | 2002 |
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2009 |
| Mahidol University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Oregon Health and Science University | Academic/Hospital | 2 | 2 | 1 | 2007 |
| Pennsylvania State University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Purdue University | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of California, Davis | Academic/Hospital | 2 | 1 | 2 | 2008 |
| University of Campinas | Academic/Hospital | 2 | 2 | 1 | 2011 |
| University of Colorado, Denver | Academic/Hospital | 2 | 2 | 2 | 2018 |
| University of Oulu | Academic/Hospital | 2 | 2 | 2 | 2007 |
Marketing (29)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Jun 5, 2017 |
| Amneal Pharmaceuticals | For profit | MKTG | Dec 11, 2019 |
| Amneal Pharmaceuticals | For profit | SYN | Dec 11, 2019 |
| Apax Partners | For profit | MKTG | Feb 25, 2011 |
| Aspen Pharmaceuticals | For profit | NDA2 | Dec 20, 2000 |
| Aurobindo Pharma | For profit | MKTG | Mar 22, 2017 |
| Aurobindo Pharma | For profit | SYN | Mar 22, 2017 |
| Barr Laboratories | For profit | MKTG | Apr 5, 2002 |
| Dr. Reddy's Laboratories | For profit | MKTG | Dec 9, 2021 |
| Duramed Research | For profit | MKTG | Aug 12, 1999 |
| Endo Pharmaceuticals | For profit | MKTG | Feb 25, 2011 |
| Exeltis | For profit | MKTG | Aug 12, 2015 |
| Glenmark Pharmaceuticals | For profit | MKTG | Apr 2, 2012 |
| Glenmark Pharmaceuticals | For profit | SYN | Apr 2, 2012 |
| Johnson and Johnson | For profit | NDA2 | Dec 14, 1992 |
| Lupin | For profit | MKTG | Mar 7, 2013 |
| Mayne Pharma | For profit | MKTG | Jan 24, 2006 |
| Mylan | For profit | MKTG | Aug 30, 2013 |
| Naari Pte Ltd | For profit | MKTG | Jun 5, 2017 |
| Novast Labs | For profit | MKTG | Jul 12, 2013 |
| Organon | For profit | MKTG | Oct 3, 2001 |
| Organon | For profit | NDA | Jul 17, 2006 |
| Organon | For profit | SYN | Jul 17, 2006 |
| Organon | For profit | NDA2 | Oct 3, 2001 |
| Teva | For profit | MKTG | Jan 13, 2021 |
| Teva | For profit | NDA2 | Apr 22, 1998 |
| Vintage | For profit | MKTG | Apr 30, 2015 |
| Vintage | For profit | SYN | Feb 25, 2011 |
| Watson Pharmaceuticals | For profit | MKTG | Jul 29, 2005 |